Answers are grounded in this paper and cite their sources.
Clonal hematopoiesis is an age-related condition characterized by somatic mutations in hematopoietic stem cells and progenitor cells, resulting in an imbalance in the production of circulating blood cells, but not meeting the diagnostic criteria for hematological malignancies. Initially regarded as a precursor state of a myeloid tumor, it has now been confirmed as an important regulator of cardiovascular disease risk. The strongest evidence pertains to atherosclerotic cardiovascular diseases, but there are also reports indicating its association with heart failure, atrial fibrillation, ischemic stroke, and thrombotic complications. Current research increasingly suggests that the mechanisms linking hematopoietic clonality to cardiovascular damage include inflammatory bone marrow hematopoiesis, alterations in the innate immune signaling pathways, activation of inflammasomes, interactions between platelets and neutrophils, and abnormal tissue remodeling. This review explores the role of innate immune reprogramming related to clonal hematopoiesis in cardiovascular diseases. Clonal hematopoiesis and trained immunity are related but distinct phenomena: clonal hematopoiesis originates from somatic mutations and clonal selection, while trained immunity refers to the continuous functional reprogramming of innate immune cells and their precursor cells. The potential fusion of these two factors may affect the generation of bone marrow cells in subsequent stress states, inflammatory responses, and interactions with cardiovascular tissues. This article focuses on three mechanism axes. Firstly, experimental models have confirmed that TET2 mutations are related to the hematopoietic process and can activate inflammasomes and the IL-1β signaling pathway. Secondly, DNMT3A mutations may affect hematopoietic function and bone marrow cell function through different epigenetic programs, although their impact on the cardiovascular system is not yet fully clear. Thirdly, the hematopoietic process related to JAK2V617F may be involved in the interaction between platelets and neutrophils, as well as the thrombotic-inflammatory process. Finally, we explore how the type of driver mutation, variant allele frequency (VAF), clonal dynamics, inflammatory activity, and cardiovascular phenotype can provide guidance for precise cardiovascular research. This comprehensive framework is currently still a mechanistic hypothesis that requires further validation, rather than an established clinical diagnosis.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: